Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts.

Stabilized methadone-maintained former heroin addicts (MTPs) treated with effective doses of methadone have markedly reduced drug craving; reduction or elimination of heroin use; normalized stress-responsive hypothalamic-pituitary-adrenal, reproductive, and gastrointestinal function; and marked improvement in immune function and normal responses to pain, all of which are physiological indices modulated in part by endogenous and exogenous opioids directed at the mu and, in some cases, the kappa-opioid systems. This study was performed to explore opioid receptor binding in MTPs. Fourteen normal, healthy volunteers and 14 long-term MTPs in treatment for 2 to 27 years and receiving 30 to 90 mg/day of methadone were studied with positron emission tomography using tracer amounts of [(18)F]cyclofoxy, an opioid antagonist that labels mu and kappa opioid receptors. Imaging was performed in the morning, 22 h after the last dose of methadone in patients, and concurrent plasma levels of methadone were determined. Five brain regions of specific interest for addiction and pain research (thalamus, amygdala, caudate, anterior cingulate cortex, and putamen) were among the six regions of highest [(18)F]cyclofoxy binding. Specific binding of [(18)F]cyclofoxy was lower by 19 to 32% in these regions in MTPs compared with those in normal volunteers. The degree to which specific binding was lower in caudate and putamen correlated with methadone plasma levels (P <.01 and P <.05, respectively), suggesting that these lower levels of binding may be related to receptor occupancy with methadone and that significant numbers of opioid receptors may be available to function in their normal physiological roles.

[1]  M. Kreek,et al.  Human spinal fluid methadone levels. , 1978, Drug and alcohol dependence.

[2]  M. Kreek Medical safety and side effects of methadone in tolerant individuals. , 1991, Journal of psychoactive drugs.

[3]  M. Sastre,et al.  mu-Opioid receptor and alpha 2-adrenoceptor agonist binding sites in the postmortem brain of heroin addicts. , 1994, Psychopharmacology.

[4]  P. Klein,et al.  Stereoselective disposition of methadone in man. , 1979, Life sciences.

[5]  Peter Herscovitch,et al.  Comparison of Bolus and Infusion Methods for Receptor Quantitation: Application to [18F]Cyclofoxy and Positron Emission Tomography , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[6]  A. Frantz,et al.  EFFECTS OF CHRONIC EXOGENOUS OPIOID ADMINISTRATION ON LEVELS OF ONE ENDOGENOUS OPIOID (β-ENDORPHIN) IN MAN , 1981 .

[7]  M. Kreek,et al.  Cocaine abuse sharply reduced in an effective methadone maintenance program. , 1999, Journal of addictive diseases.

[8]  Robert F. Dannals,et al.  Increased mu opioid receptor binding detected by PET in cocaine–dependent men is associated with cocaine craving , 1996, Nature Medicine.

[9]  A. Ho,et al.  Pain Perception in Drug-Free and in Methadone-Maintained Human Ex-Addicts , 1979, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[10]  W C Eckelman,et al.  S‐[18F]Acetylcyclofoxy: a useful probe for the visualization of opiate receptors in living animals , 1984, FEBS letters.

[11]  Peter Herscovitch,et al.  PET imaging of opiate receptor binding in human epilepsy using [18F]cyclofoxy , 1992, Epilepsy Research.

[12]  R. Rothman,et al.  An examination of the opiate receptor subtypes labeled by [3H]cyclofoxy: An opiate antagonist suitable for positron emission tomography , 1988, Biological Psychiatry.

[13]  C. Pert,et al.  Probes for narcotic receptor mediated phenomena. XI: Synthesis of 17-methyl and 17-cyclopropylmethyl-3,14-dihydroxy-4,5α-epoxy-6β-fluoromorphinans (foxy and cyclofoxy) as models of opioid ligands suitable for positron emission transaxial tomography , 1985 .

[14]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[15]  W C Eckelman,et al.  Radiosynthesis of [18F]3-acetylcyclofoxy: a high affinity opiate antagonist. , 1985, The International journal of applied radiation and isotopes.

[16]  M. Kreek,et al.  MEDICAL COMPLICATIONS IN METHADONE PATIENTS * , 1978, Annals of the New York Academy of Sciences.

[17]  J. Krystal,et al.  Psychopharmacology: The Third Generation of Progress , 1989, The Yale Journal of Biology and Medicine.

[18]  D. Lissin,et al.  mu-Opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. , 1998, Molecular pharmacology.

[19]  S. Plevy,et al.  ACTH, cortisol and β-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans , 1984, Neuropeptides.

[20]  M. Kreek Opiates, opioids and addiction. , 1996, Molecular psychiatry.

[21]  Kreek Mj Plasma and urine levels of methadone. Comparison following four medication forms used in chronic maintenance treatment. , 1973 .

[22]  M. Kreek,et al.  Repeated cocaine administration upregulates kappa and mu, but not delta, opioid receptors. , 1994, Neuroreport.

[23]  M. Kreek,et al.  Steady-state methadone in rats does not change mRNA levels of corticotropin-releasing factor, its pituitary receptor or proopiomelanocortin. , 1996, European journal of pharmacology.

[24]  C. Inturrisi,et al.  The levels of methadone in the plasma in methadone maintenance , 1972, Clinical pharmacology and therapeutics.

[25]  J A Tischfield,et al.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  V. Yuferov,et al.  Acute “binge” cocaine increases mu-opioid receptor mRNA levels in areas of the rat mesolimbic mesocortical dopamine system , 1999, Brain Research Bulletin.

[27]  M. Kreek,et al.  Narcotic blockade. , 1966, Archives of internal medicine.

[28]  Richard E Carson,et al.  Opiate receptor avidity and cerebral blood flow in Alzheimer's disease , 1997, Journal of the Neurological Sciences.

[29]  M. Kreek,et al.  Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism. , 1998, Alcoholism, clinical and experimental research.

[30]  M. Kreek,et al.  Chronic cocaine alters brain mu opioid receptors , 1992, Brain Research.

[31]  N. Chiorazzi,et al.  Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. , 1989, The Journal of pharmacology and experimental therapeutics.

[32]  M. Kreek Rationale for maintenance pharmacotherapy of opiate dependence. , 1992, Research publications - Association for Research in Nervous and Mental Disease.

[33]  J. Mazziotta,et al.  Rapid Automated Algorithm for Aligning and Reslicing PET Images , 1992, Journal of computer assisted tomography.

[34]  G F Koob,et al.  Drug dependence: stress and dysregulation of brain reward pathways. , 1998, Drug and alcohol dependence.

[35]  C. Beasley,et al.  TSH response to TRH and haloperidol response latency in psychoses , 1988, Biological Psychiatry.